Full-Time

Cardiac PET Account Manager

Updated on 8/24/2026

Deadline 8/28/26
GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

Compensation Overview

$153.6k - $230.4k/yr

+ Performance-based cash bonus + Long-term incentives

No H1B Sponsorship

Remote in USA + 1 more

More locations: Norwalk, CT, USA

Remote

Must reside in the territory and travel overnight at least 30% based on business needs.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Microsoft Office
Sales
Forecasting
CRM
Marketing

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • A bachelor's degree from an accredited university or college, or certification through the Nuclear Medicine Technology Certification Board or the American Registry of Radiologic Technologists.
  • At least 5 years of sales experience in a healthcare facility, including contracting and calling on physicians and office staff.
  • A proven history of sales success, developing, organizing, and implementing territory plans, meeting and exceeding sales targets, and penetrating new accounts, markets, and competition through prospecting, lead qualification, sales, and negotiations.
  • Willingness to reside in the territory, travel overnight at least 30% based on business needs, and work some weekends for trade show attendance.
Responsibilities
  • Develop and execute a territory business plan to grow Flyrcado market share across hospitals, imaging centers, cardiac centers, mobile imaging, Department of Defense, and Veterans Affairs facilities.
  • Build relationships with imaging and cardiology referral sources, payers, societies, and other influence networks to achieve access, sales, and volume goals.
  • Conduct regular business analyses of local customers, payers, competition, and stakeholders, and update business plans accordingly.
  • Achieve the quarterly and yearly operating plan for the territory, customer satisfaction, and retention.
  • Position Flyrcado through clinical knowledge, marketing assets, and education programs to increase product awareness and utilization.
  • Advise imaging centers and cardiologists on their goals, equipment, workflows, and implementation of Flyrcado.
  • Identify top referring cardiologists and influence decision-making criteria to increase Flyrcado awareness and utilization.
  • Prioritize projects and opportunities, monitor performance dashboards, analyze results, and execute actionable sales efforts.
  • Collaborate with market access teams to optimize payer contract implementation and satisfaction.
  • Collaborate with pharmacy channel partners and Product Development and Diagnostics Application Specialists teams to meet product delivery and education goals.
  • Plan and conduct customer calls, understand customer needs, craft solutions, and drive utilization.
  • Monitor territory performance and collaborate with internal and external partners on next steps.
  • Conduct virtual selling and cold calling while holding live customer meetings where possible.
  • Provide pricing strategy, negotiate prices, manage contracts, and ensure pricing compliance.
  • Forecast territory orders and sales and submit weekly progress reports.
  • Represent GE HealthCare at healthcare conferences and seminars.
  • Drive total business to GE HealthCare in alignment with the goals and clinical benefits of its HCS and National teams.
  • Promote a compliant and ethical culture and adhere to regulatory standards.
  • Complete additional commercial projects and initiatives as required.
Desired Qualifications
  • Experience selling or leading in a highly matrixed environment and managing large accounts.
  • Nuclear medicine and nuclear cardiac industry knowledge.
  • Experience with product launches and Pharmacy and Therapeutics Committees.
  • Strong analytical, oral, presentation, and written skills, with proficiency in Microsoft Office and customer relationship management systems.
  • Ability to work independently and collaboratively while managing multiple stakeholders and competing priorities through effective organizational, people, and time management.
  • Ability to mentor non-senior Cardiac PET Account Managers as requested by leadership and manage special commercial projects.
  • Ability to use internal reporting to manage account plans and identify patterns and growth opportunities.
  • Ability to apply traditional and nontraditional problem-solving techniques to improve performance and company effectiveness.
  • Ability to build rapport with employees and external contacts, including physicians and office staff, and respond appropriately to their needs.
  • Ability to achieve objectives while complying with regulatory guidelines.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11.1% and backlog hit a record $23.9 billion.
  • August 3, 2026 Invenia ABUS Prime targets dense-breast screening demand and remote reading.
  • Tariff refunds and supply-chain shifts lifted Q2 2026 profits, while 2026 guidance stayed reaffirmed.

What critics are saying

  • Patient Care Solutions fell 13.5% in Q2 2026, and management is reviewing sale options.
  • CFO Jay Saccaro exits August 14, 2026, adding execution risk during the PCS review.
  • Siemens Healthineers and Philips pressure GEHC in imaging; stalled innovation erodes hospital preference.

What makes GE Healthcare unique

  • GE HealthCare combines imaging, pharmaceutical diagnostics, and MIM software across one workflow stack.
  • Its August 2026 ABUS Prime and Allia upgrades monetize installed bases without replacements.
  • FDA-cleared AI tools like ProtégéAI+ 2.0 shorten oncology workflows and deepen switching costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.

Yahoo Finance
Jul 29th, 2026
GE HealthCare beats profit estimates on imaging demand and $129M tariff refunds

GE HealthCare exceeded Wall Street's second-quarter profit estimates, driven by robust demand for diagnostic and imaging devices and tariff refunds from the Trump administration. The medical device maker reported net income of $561 million, up from $486 million last year, which included $129 million in tariff refunds. Revenue reached $5.30 billion for the quarter ending 30 June, surpassing the estimated $5.26 billion. Sales in imaging devices grew 7.9%, whilst pharmaceutical diagnostics jumped 15.6%. Adjusted earnings per share came in at $1.13, beating analysts' estimate of $1.04. The company's shares rose 12% in premarket trading. However, GE HealthCare noted that geopolitical instability, including Middle East conflicts, negatively affected costs, supply chains and logistics during the quarter.

Yahoo Finance
Jul 29th, 2026
GE HealthCare beats estimates with record orders, shares jump 9%

GE HealthCare Technologies reported second-quarter results that exceeded Wall Street expectations. Adjusted earnings per share reached $1.13, beating the $1.04 consensus estimate, whilst revenue hit $5.3 billion, surpassing the $5.26 billion forecast and marking a 5.7% year-on-year increase. The company delivered record organic orders growth of 11.1% with a book-to-bill ratio of 1.15 times and backlog of $23.9 billion. Organic revenue grew 3.5%, driven by strength in Pharmaceutical Diagnostics and Advanced Imaging Solutions. Patient Care Solutions revenue declined 13.5% year-on-year. Adjusted EBIT margin came in at 14.2%, down 40 basis points from the prior year. Shares jumped 9% premarket following the release. GE HealthCare reaffirmed its full-year guidance, projecting organic revenue growth of 3.0% to 4.0% and adjusted EPS between $4.80 and $5.00.

Fortune
Jul 23rd, 2026
GE's $593B comeback: How CEO Larry Culp pulled off history's greatest turnaround

GE CEO Larry Culp has orchestrated what many industry leaders consider the greatest corporate turnaround in modern business history. When he took over in 2018, GE's market capitalisation stood at $96 billion, down over 80% from its 2000 peak, with $150 billion in crushing debt. Today, the three companies Culp created from GE's breakup — GE Aerospace, GE Vernova, and GE HealthCare — have a combined market value of $689 billion. The trio has delivered annualised returns of roughly 30% since Culp's arrival, double the S&P 500's performance. GE Vernova has jumped over 600% whilst GE Aerospace has risen more than 160%. Culp's approach centred on lean manufacturing principles learnt from the Toyota Production System. He decentralised operations, eliminated three-quarters of central staff positions, and fostered a culture encouraging managers to spotlight problems rather than successes.